ERBB2 and invasive ductal breast carcinoma: Table 3 indicates that according to the multivariate analysis in the HR+/HER2+ group, CT alone (adjusted HR=2.59, 95% CI, 1.64–4.10, p<0.001, reference: TT) as first-line therapy and other tumor histological types (adjusted HR=1.99, 95% CI, 1.14–3.48, p=0.016, reference: invasive ductal carcinoma) were independently associated with worse PFS.